Guiding an Improved Dementia Experience Model (GUIDE)

Analysis updated November 9, 2026

Strategic questions for your team

Do we have sufficient Medicare FFS patient volume with dementia diagnoses to reach the 200-aligned-beneficiary threshold CMS encourages by end of Performance Year 2 — and can our current referral networks (primary care, neurology, hospital discharge planning, community-based organizations) generate enough pipeline to sustain that census through June 30, 2032 without triggering the automatic unalignment trigger of eight consecutive months without a DCMP or respite claim?
What is our projected net revenue per aligned patient under the PY 2026 DCMP base rates — specifically $157/month for the first 6 months and $68/month thereafter for low-complexity dyad patients, scaling to $377/$231 for high-complexity dyad patients — after accounting for the Performance-Based Adjustment, the Population and Income Adjustment, the Medicare Economic Index adjustment, and the Geographic Adjustment Factor, and do those blended rates cover our fully-loaded cost of delivering all nine care delivery domains including 24/7 helpline, mandatory home visits for moderate-to-severe patients, and care navigator salaries?
Can we staff and sustain a compliant interdisciplinary care team — minimally a trained care navigator and a clinician meeting GUIDE's 'dementia proficiency' criteria (25% cognitive-impairment or 65+ patient panel, or specialty designation in neurology, psychiatry, geriatrics, geriatric psychiatry, behavioral neurology, or geriatric neurology) — and if the dementia-proficient clinician is a non-physician, do we have a physician medical director in place to meet the oversight requirement?
Does our organization currently provide at least 6 of the 9 GUIDE care delivery domains (comprehensive assessment, care planning, ongoing monitoring, medication reconciliation, 24/7 access, care coordination/transitional care management, referrals/community connections, caregiver education and support, respite) with an active interdisciplinary team for at least 12 months — qualifying us for the Established Program Track starting July 1, 2024 — or must we enter the New Program Track's pre-implementation year and, if so, do we meet the safety-net provider definition to receive the one-time $75,000 geographically-adjusted Infrastructure Payment?
Are we operationally ready to meet all GUIDE data and reporting obligations — including submitting Patient Assessment and Alignment Forms (PAAFs) via the CMS HDR application within 60 days of the dementia staging tool administration date, conducting annual reassessments between days 306–425 of each assessment cycle, reporting CDR or FAST dementia staging scores, PROMIS-10 global health scores, and ZBI-22 caregiver burden scores, and maintaining a certified EHR meeting ONC CEHRT standards (42 CFR 414.1305) — and have we budgeted for the administrative infrastructure (data custodians, FHIR endpoint capability, Participant Portal management) required to avoid claim denials and alignment failures?
How will we deliver and finance GUIDE Respite Services — up to $2,500 annually per eligible patient in the moderate-complexity dyad tier (CDR 2–3/FAST 5–7, ZBI 0–60) and high-complexity dyad tier (CDR 2–3/FAST 5–7, ZBI 61–88) and low-complexity individual tier — including mandatory in-home respite, and have we identified, contracted, and obtained CMS approval for Partner Organizations (home health agencies, adult day centers, facility-based respite providers) who can deliver these services within our zip-code service area, given that we must pass 100% of respite payments from CMS directly to those Partner Organizations?
What is our exposure to the Performance-Based Adjustment on the DCMP — which is applied based on five measures including Use of High-Risk Medications in Older Adults, Quality of Life Outcome for People with Neurological Conditions, Caregiver Burden, Total Per Capita Cost, and Long-Term Nursing Home Stay rate — and do we have baseline data, clinical protocols, and care management workflows in place to perform competitively on these metrics, particularly the novel Caregiver Burden and Long-Term Nursing Home Stay rate measures being developed specifically for GUIDE?
If we plan to serve patients residing in Residential Care Communities (RCCs) — assisted living facilities, group homes, adult family homes, board and care homes — have we established compliant Partner Organization Arrangements with each RCC before aligning any patients residing there, obtained CMS approval of each RCC as a Partner Organization, understood that all RCC-residing patients are assigned to the flat RCC tier ($180/month new, $70/month established in PY 2026) regardless of dementia severity or caregiver status, and confirmed those patients are categorically ineligible for the $2,500 annual GUIDE Respite benefit?
How does GUIDE participation interact with our existing CMMI model participation — specifically, if we are in the Medicare Shared Savings Program or another ACO model, have we mapped which DCMP-covered services (including CPT 99483, chronic care management codes 99487–99491, transitional care management codes 99495–99496, advanced primary care management G0556–G0558, and community health integration G0019/G0022) will no longer be separately billable under FFS for aligned patients, and have we modeled the net financial impact of bundling those services into DCMP rates versus our current FFS revenue for this population?
Have we developed a compliant Health Equity Plan that identifies disparities in our dementia patient population and maps strategies to reduce them over the model period, established workflows to screen all aligned patients and caregivers for sociodemographic characteristics and health-related social needs (with opt-out rights preserved), and positioned our organization to capture the Population and Income Adjustment — which increases DCMP payments for low-income patients from underserved communities and decreases them for higher-income patients — as a financial incentive to serve dual-eligible and safety-net populations who have higher dementia prevalence and more unmet care needs?

Traps and concerns

60-Day PAAF Submission Window Billing Trap
Participants must submit the completed Patient Assessment and Alignment Form (PAAF) to CMS within 60 days of the date the dementia staging tool (CDR or FAST) was administered during the initial comprehensive assessment. Critically, participants cannot bill any GUIDE-specific G-codes — including the first month's DCMP — until they receive final confirmation through the Beneficiary Alignment Report, which CMS delivers within 15 business days of PAAF receipt. If the PAAF is submitted late (beyond the 60-day window), CMS may reject alignment entirely, meaning the participant absorbs the full cost of the comprehensive assessment visit with no DCMP recovery. For high-volume programs targeting the recommended minimum of 200 aligned beneficiaries, a systematic PAAF submission delay across even 20-30 patients per quarter could result in tens of thousands of dollars in unrecoverable care delivery costs, since the DCMP covering the initial assessment month ($157–$409 at new patient base rates for PY 2026) will not be paid for rejected alignments.
Eight-Consecutive-Month Claims Gap Auto-Unalignment
CMS will automatically unalign a patient — without participant-initiated action — if the participant fails to file claims for the DCMP or GUIDE Respite Services for eight consecutive calendar months. For dementia patients in the low complexity dyad tier, minimum contact frequency is only quarterly, creating a structural scenario where care delivery can occur without a billable GUIDE care delivery service in intervening months. Participants who misinterpret the quarterly touchpoint requirement as permission to skip billing for non-contact months risk triggering this auto-unalignment mechanism. Once unaligned, the participant must restart the full voluntary alignment process — including a new comprehensive assessment, new PAAF submission, and a new 6-month 'new patient' payment period at higher base rates ($157–$409/month) before transitioning to established patient rates ($68–$231/month). For large panels, this creates both administrative burden and a perverse financial reset that may disadvantage participants who have already invested in the higher-intensity onboarding period.
RCC Partner Approval Gap and 60-Day Transition Cliff
Beginning PY 2026, patients residing in Residential Care Communities (RCCs) must be aligned to an RCC-specific tier ($180/month new patient, $70/month established patient base rates), and the RCC must be CMS-approved as a Partner Organization with a compliant Partner Organization Arrangement in place before any patient residing in that RCC can be aligned. If an already-aligned patient moves to an RCC where the participant lacks an approved Partner Organization Arrangement, the participant has only a 60-day transition window to obtain CMS approval. RCC Partner approval includes program integrity screening, and the Participation Agreement imposes enhanced disclosure and oversight requirements under Section 3.06. If CMS approval cannot be secured within 60 days, the participant must submit an unalignment PAAF and coordinate care transition — losing all future DCMP revenue for that patient. Participants serving geographically dispersed patient populations with multiple potential RCC destinations face significant operational exposure if they have not proactively pre-approved a broad network of RCC partners. Memory Care Units are categorically ineligible, with only a 15-day transition window, and participants must submit final billing claims within 30 days of the unalignment effective date or forfeit that revenue.
Performance-Based Adjustment Retroactive Revenue Reduction
The DCMP is not a fixed payment — it is subject to a Performance-Based Adjustment (PBA) applied retroactively across five performance measures: Use of High-Risk Medications in Older Adults, Quality of Life Outcome for People with Neurological Conditions, Caregiver Burden (a novel measure being developed specifically for GUIDE), Total Per Capita Cost, and Long-Term Nursing Home Stay rate. The PBA is applied to the base DCMP rates after the performance year concludes, meaning participants receive monthly base rate payments throughout the year and then face potential downward reconciliation. Two of the five measures — Caregiver Burden and Long-Term Nursing Home Stay rate — are newly developed metrics without established benchmarking data, creating significant uncertainty about scoring thresholds and performance distribution across the 292 current participants. A participant operating with thin margins on the established patient base rates ($68–$231/month) who receives a downward PBA adjustment faces the risk that monthly payments were effectively insufficient to cover care delivery costs. Participants should model worst-case PBA scenarios against their per-patient cost structures before scaling panel size.
Infrastructure Payment Repayment Obligation and Termination Risk
New Program Track participants who qualified as safety-net providers received a one-time Infrastructure Payment of $75,000 (geographically adjusted using the Medicare PFS Geographic Adjustment Factor). However, this payment carries two significant compliance risks. First, participants must repay any unspent Infrastructure Payment funds to CMS by the end of PY 2025 (June 30, 2026), requiring meticulous expenditure tracking against CMS-defined allowed uses. Second, and more critically, participants who received the Infrastructure Payment and are subsequently terminated from GUIDE — including for failure to meet care delivery, CEHRT, or practitioner roster requirements by the May 1, 2025 New Program Track deadline — are contractually required to repay the entire Infrastructure Payment to CMS. New Program Track participants that invested the $75,000 in staff hiring and infrastructure buildout but then fail CMS's pre-performance year compliance verification face a scenario of both forfeited investment and mandatory full repayment, creating a potential $150,000+ net negative financial event for a small safety-net provider.
CEHRT Interoperability and PAAF Automation Fragility
Participants are required to use an electronic health record platform meeting CMS and ONC standards for Certified Electronic Health Record Technology (CEHRT) as defined at 42 CFR 414.1305, updated to the required version of USCDI. Beyond the baseline CEHRT requirement, the PAAF submission process offers two data population pathways — Individual PAAF Entry via the GUIDE Participant Portal (limited to ten approved users per participant) and FHIR endpoint submission via HL7 FHIR Questionnaire Response Resource. CMS explicitly warns that it 'may update the PAAF periodically to adjust to model needs,' and that 'participants developing an automated data entry process for the PAAF should be aware that periodic changes to the PAAF template will require updates to their automated solution.' Participants who invest in custom FHIR integration or automated PAAF workflows face ongoing maintenance obligations whenever CMS modifies the template — with no guaranteed advance notice timeline. A broken PAAF automation at scale (for participants approaching or exceeding the 200-patient minimum threshold) risks missed 60-day submission windows across multiple patients simultaneously, triggering cascading alignment failures and billing revenue loss that may not be recoverable.
Voluntary Alignment Exclusivity and Patient Switching Liability
The GUIDE Model requires patients to consent to receive GUIDE care delivery services exclusively from a single participant. When a patient voluntarily realigns to a different GUIDE participant, the original participant must: notify CMS within 15 business days, provide care transition information to the new participant within 15 days of outreach, and complete all required medical record documentation. The Participation Agreement explicitly prohibits participants, GUIDE Practitioners, Partner Organizations, or any associated individuals from attempting to influence a patient's alignment decision — violations could trigger program integrity review or termination. The financial exposure is material: a participant that has invested in the onboarding, comprehensive assessment, and 6-month new patient period (receiving $157–$409/month) may lose a patient immediately after transitioning to the lower established patient rate ($68–$231/month) — the point at which the long-term financial return of the relationship was expected to materialize. For high-dementia-density markets with multiple GUIDE participants competing within the same service area zip codes, patient switching represents a structurally underappreciated revenue concentration risk, particularly for smaller programs with panels close to the 200-patient minimum threshold.